Flputnam Investment Management Co. Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Flputnam Investment Management Co. trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 50.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,962 shares of the medical research company's stock after selling 1,977 shares during the period. Flputnam Investment Management Co.'s holdings in Charles River Laboratories International were worth $362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Empirical Finance LLC grew its stake in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after buying an additional 53 shares in the last quarter. Fiduciary Financial Group LLC raised its position in shares of Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. M&T Bank Corp boosted its holdings in shares of Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after acquiring an additional 66 shares during the period. Finally, Covestor Ltd grew its position in shares of Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock valued at $65,000 after purchasing an additional 95 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group dropped their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research report on Monday. Barclays reduced their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 18th. StockNews.com cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average price target of $198.36.

Charles River Laboratories International Trading Up 4.1 %

Shares of Charles River Laboratories International stock traded up $6.93 during midday trading on Friday, reaching $176.20. The company had a trading volume of 1,169,008 shares, compared to its average volume of 698,204. The stock has a fifty day moving average price of $169.35 and a 200 day moving average price of $186.07. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The firm has a market cap of $9.01 billion, a PE ratio of 1,174.68, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).